MyChesCo on MSN12h
Aclaris Therapeutics Launches Phase 2a Trial for ATI-2138 in Atopic Dermatitis
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has commenced its Phase 2a clinical trial for ATI-2138, an innovative oral covalent ...
The Pharma Letter17h
Atopic dermatitis market set for major growth
The atopic dermatitis (AD) market is projected to reach $16.7 billion by 2030, according to GlobalData. New therapies like ...
HealthDay on MSN21h
FDA Approves Ebglyss for Moderate-to-Severe Atopic Dermatitis
The U.S. Food and Drug Administration has approved Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 years and ...
GlobalData on MSN1d
Aclaris doses first subject in Phase IIa atopic dermatitis treatment trial
Aclaris Therapeutics has dosed the first subject in the Phase IIa clinical trial of ATI-2138 to treat moderate to severe ...
dvm3605h
Treatment for allergic skin conditions receives FDA approval
The FDA announced earlier today that ilunocitinib tablets (Zenrelia; Elanco) has received its approval. The latest drug from ...
Medscape1d
Roflumilast Cream 0.15% Improves Atopic Dermatitis Symptoms in Phase 3 Studies
Roflumilast cream 0.15% was well tolerated and significantly improved symptoms in adults and children with mild to moderate atopic dermatitis (AD) in two phase 3 trials. The two phase 3 randomized ...
infectiousdiseaseadvisor.com13h
Pediatric Atopic Dermatitis: Dupilumab Normalizes Inflammatory Biomarkers
Dupilumab decreases general and type 2 inflammatory biomarker levels in children with moderate to severe atopic dermatitis.
Everyday Health2d
Ebglyss, a New Biologic Treatment for Atopic Dermatitis, Gets FDA Approval
Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...
pulmonologyadvisor13h
Adbry Autoinjector Now Available for Adults With Atopic Dermatitis
A new single-dose autoinjector presentation of Adbry is now available for use in the treatment of moderate to severe atopic dermatitis.
The American Journal of Managed Care3d
FDA Approves Lebrikizumab For Patients Aged 12 and Older With Moderate to Severe Atopic Dermatitis
The FDA has approved lebrikizumab (Ebglyss; Eli Lilly) as a new first-line biologic treatment for patients aged 12 and older ...
Organon to buy skin therapy developer Dermavant for up to $1.2 billion
(Reuters) -Healthcare company Organon said on Wednesday it has agreed to acquire skin therapy developer Dermavant, a unit of Roivant, for up to $1.2 billion. Organon will make an upfront payment of ...